M 16287

Overview

M 16287 is an orally active aldose reductase inhibitor, with an IC 50 of 0.08 μM in rats and 0.25 μM in cattle. M 16287 improves lens fiber swelling and vacuolization, prevents galactitol accumulation, delays inositol depletion, inhibits glutathione reduction, restores the NADPH/NADP + ratio to normal, and normalizes lens Na + content and Na + /K + ratio. M 16287 prevents galactose-induced cataract formation in rats. M 16287 improves motor nerve conduction velocity in diabetic rats, partially alleviates histopathological changes in the sciatic nerve, and inhibits sorbitol accumulation. M 16287 can be used in studies related to cataracts and diabetic neuropathy.

Application

Products | Products > Disease Areas > Cataract | Products > Disease Areas > Type 1 Diabetes | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Visual System Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Aldose Reductase

Product Information

• Catalog No.: HY-165518
• CAS No.: 128851-55-8
• Molecular Formula: C11H7ClN2O5S
• Molecular Weight: 314.70
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source